

WEST PHARMACEUTICAL SERVICES INC  
Form 8-K  
April 17, 2012

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – April 17, 2012

WEST PHARMACEUTICAL  
SERVICES, INC.

(Exact name of registrant as specified in its charter)

|                                                                                               |                                       |                                                    |
|-----------------------------------------------------------------------------------------------|---------------------------------------|----------------------------------------------------|
| Pennsylvania<br>(State or other jurisdiction<br>of Incorporation)                             | 1-8036<br>(Commission File<br>Number) | 23-1210010<br>(IRS Employer<br>Identification No.) |
| 101 Gordon Drive, PO Box<br>645, Lionville, PA<br>(Address of principal<br>executive offices) |                                       | 19341-0645<br>(Zip Code)                           |

Registrant's telephone number, including area code: 610-594-2900

Not Applicable  
(Former name or address, if changed since  
last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 2.02. Results of Operations and Financial Condition

On April 17, 2012, West Pharmaceutical Services, Inc. (Company) issued a press release pre-announcing its first quarter 2012 earnings per share and updating its 2012 earnings per share guidance. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01. Financial Statements and Exhibits

- (d) Exhibits
- |         |                                                               |
|---------|---------------------------------------------------------------|
| Exhibit | West Pharmaceutical Services, Inc. Press Release, dated April |
| 99.1    | 17, 2012                                                      |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST  
PHARMACEUTICAL  
SERVICES, INC.

/s/ William J. Federici  
William J. Federici  
Vice President and  
Chief Financial Officer

April 17, 2012

---

EXHIBIT INDEX

| Exhibit No. | Description                                                            |
|-------------|------------------------------------------------------------------------|
| 99.1        | West Pharmaceutical Services, Inc. Press Release, dated April 17, 2012 |

